The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The ...
Related Keywords
United States , Chicago , Illinois , American , Ciltacabtagene Autoleucel , Hemophagocytic Lymphohistiocytosis , Saadz Usmani , Sen Zhuang , Janssen Biotech Inc , European Hematology Association Congress , American Society Of Clinical Oncology , European Hematology Association , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Congress Abstract , American Society Of Clinical Oncology Annual Meeting , United States Inc , Clinical Research , American Cancer Society , None Of Janssen Biotech Inc , Exchange Commission , Companies Of Johnson , European Medicines Agency , Johnson , Clinical Oncology , Annual Meeting , Confidence Interval , Myeloma Service , Memorial Sloan Kettering Cancer Center , Earlier Lines , Vice President , Janssen Research , Janssen Biotech , Legend Biotech , Important Safety , Release Syndrome , Effector Cell Associated Neurotoxicity Syndrome , Macrophage Activation Syndrome , Risk Evaluation , Mitigation Strategy , Nerve Palsies , Recurrent Cytopenias , Igg Hypersensitivity Reactions , Use Machines , Prescribing Information , Boxed Warning , Pharmaceutical Companies , Infectious Diseases , Janssen Pharmaceutica , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Clinical Oncology Annual , Refractory Multiple Myeloma , Hematology Association , Correlative Analyses , Updated Clinical Data , Statistics About Multiple Myeloma ,
comparemela.com © 2020. All Rights Reserved.